Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT»

Objective of the work was the production of recombinant vaccine «RevaxVZT» in tablet dosage form against hepatitis B and pathogenic for humans orthopoxviruses for further clinical trials. Materials and methods. Recombinant strain b7.5S2-S of vaccinia virus carrying a DNA fragment of hepatitis B virus inserted into thymidinekinase gene was used as an active component of the vaccine. Microbiological, virological, physical, physical and chemical, and biotechnological methods were used for studying the quality of the drug and technological processes. Results and discussion. Results of technological control for semi-finished products and final products of the vaccine “Revax VZT” showed the possibility of using certified hardware-processing line of “TEOVac” for its manufacturing. Same technology can be potentially used with other live tableted embryo smallpox vaccines too. For the development of the vaccine “Revax VZT” with the specific activity of not less than 1.0·10⁷ PFu/tablet, it is necessary to use a dry virus-containing material with activity not less than 2.0·10⁸ PFU/g which is produced by freeze-drying of liquid virus-containing preparation with the activity of not less than 1.0·10⁸ PFU/g, preferentially propagated from chorionic allantoic membranes of chicken embryos as a substrate for viral biomass accumulation.

1. Fundamentals of the state policy of the Russian Federation in the field of ensuring chemical andbiological safety for the_period up to 2025 and beyond: Decree of the President of the Russian Federation of March 11,2019 No. 97. (Cited 11 Mar 2019). lInternetj. Available from: https://www.garant.ru/products/ipo/prime/doc/72092478/.

2. Buonaguro F.M., Tornesello M.L., Buonaguro L. The XIX century smallpox prevention in Naples and the risk of transmission of human blood related pathogens. J. Transl. Med. 2015; 13:33. DOI: 10.1186/s12967-015-04t30-9.

3. Okoli A., Okeke M.I., Tryland M., Moens U. CRISPR/ Cas9 - advancing orthopoxvirus genome editing for vaccine and vector development. Viruses. 2018; 10(1). pii: E50. DOI: 10.3390/v10010050.

4. Podkuyko V.N., Vorobyov A.A., Krasnyansky V.P., Patrikeev G.T., Mikhailov V.V., Dorokhina T.V., Makhlai A.A., Dykanov G.A. Oral immunization is a way to increase the safety of a recombinant vector (vaccine virus). [Bulletin of the Russian Academy of Medical Sciences!. 1993' 2'39-45

5. Pavot V, Sebastian S., Turner A.V., Matthews J., Gilbert S.C. Generation and production of modified vaccinia virus Ankara (MVA) as a vaccine vector. Methods Mol. Biol. 2017; 1581:97-119. DOI: 10.1007/978-1-4939-6869-5-6.

6. Omura N., Yoshikawa T.yFujii H., Shibamura M., Inagaki T., Kato H., Egawa K., Harada S., Yamada S., Takeyama H., Saijo M. A novel system for constructing a recombinant highly-attenuated vaccinia virus strain (LC16m8) expressing foreign genes and its application for the generation of LC16m8-based vaccines against Herpes Simplex virus 2. Jpn. J. Infect. Dis. 2018; 71(3):229-33. DOI: 10.7883/yoken.JJID.2017.458.

7. Li Y., Chen S., Fang J, Zhu Y., Bai B., Li W., Yin X., Wang J., Liu X., Han J., Li X., Sun L., Jin N. Construction of an attenuated Tian Tan vaccinia virus strain by deletion of TA35R and TJ2R genes. Virus Res. 2018; 256:192-200. DOI: 10.1016/j.virusres.2018.06.017.

8. Cavenaugh J.S., Awi D., Mendy M., Hill A.V., Whittle H McConkey S.J. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One. 2011; 6(2):e14626. DOI: 10.1371/journal.pone.0014626.

9. Backes S., Jager C., Dembek C.J., Kosinska A.D., Bauer T., Stephan A.S., Dislers A., Mutwiri G., Busch D.H., Babiuk L.A., Gasteiger G., Protzer U. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. Vaccine. 2016; 34(7):923-32. DOI: 10.1016/j.vaccine.2015.12.060.

10. Muratov P.Yu., Belyaev A.S., Dmitriev I.P, Netesov S.V., Rukavishnikov M.Yu. Live recombinant vaccine for the prevention of hepatitis B and smallpox for cutaneous use and method for its preparation. RF patent for the invention No. 2073524(13) dated 13.05.1999.

11. Pavlova L.I., Gorbunov M.A., Borisova V.N., Krasilnikov I.V, Noskova A.V, Lytsar B.N., Skvortsov S.V, Belyakova E.A., Yakovleva I. .M., Korovin Yu.P., Belchenko A.V, Titov I.A., Budanov M.V. Domestic recombinant hepatitis B vaccine (results of controlled trials). Voprosy virusologii [Problems of virology]. 1996;

12. Vedernikov B.F., Generalov V.M., Evtin N.K., Kochneva G.V., Mikheev M.V., Netesov S.V., Petrishchenko V.A., Pyankov O.V., Sandakhchiev L. .S., Safatov A.S., Sergeev A.A., Sergeev A.N., Shishkin A.V., Shishkina L.N. Tableted live recombinant bivaccine “Revax VKT” against smallpox and hepatitis B and the method for its preparation. RF patent No. 2242246 of 15.02.2002.

13. Plyasunov I.V., Sergeev A.A., Sergeev Al.A., Petrishchenko V.A., Shishkina L.N., Generalov V.V., Safatov A.S., Sandakhchiev L.S., Udut V .V, Melnikov S.A., Podkuyko V.N. Clinical studies of recombinant bi-vaccine against smallpox and hepatitis B for oral ad-ministration in conditions of double vaccination. Voprosy virusologii [Problems of virology], 2006; 51(2):31—5.

14. Bondarev' VP., Terentyev A.I., Melnikov S.A., Bondareva T.A. The introduction of TEOVac smallpox vaccine into serial production to ensure the biological safety of the population of the Russian Federation. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2010; 2:66-8. DOI: 10.21055/0370-1069-2010-2(104)-66-68.

15. Chernos VI., Chelyapov N.V, Antonova T.P., Ralikhina L.E., Unanov S.S., Altstein A.D., Zakharova L.G., Fodor I.I., Bendukidze K .A., Komarov F.I., Belyshev B.P., Dmitriev A.V, Andzhaparidze O.G. Testing the safety, vaccination, reactogenicity and antigenic properties of a live recombinant smallpox and hepatitis B vaccine in a volunteer experiment. Voprosy virusologii [Problems of virology]. 1990; 35(2):132—5.

16. Graham B.S., Belshe R.B., Clements M.L., Dolin R., Corey L., Wright P.F., Gorse G.J., Midthun K., Keefer M.C., Roberts N.J., Schwartz D.H., Agosti J.M., Fernie B.F., Stablein D.M., Montefiori D.C., Lambert J.S., Hu S.-L., Esterlitz J.R., Lawrence D.N., Koff W.C. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J. Infect. Diseases. 1992; 166 (2):244-52. DOI: 10.1093/infdis/166.2.244.